Close Menu

NEW YORK – A recent pilot study of Pfizer's PARP inhibitor talazoparib (Talzenna) suggests that it might work as a neoadjuvant treatment for women with triple negative breast cancer and BRCA germline mutations.

Pfizer is conducting its own Phase II trial, results of which are still likely more than a year away, but the pilot, conducted by researchers from MD Anderson Cancer Center, showed promising results.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.